BACKGROUND: Fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and phosphorus all have been proposed as plasma biomarkers for the development of coronary heart disease (CHD) in individuals with normal renal function. METHODS: In a nested case-control study of men in the Health Professionals Follow-up Study, free of diagnosed cardiovascular disease at blood draw, we prospectively examined associations between plasma FGF23, PTH, and phosphorus and risk of CHD. During 10 years of follow-up, 422 men developed nonfatal myocardial infarction or fatal CHD. Controls were selected in a 2:1 ratio and matched for age, date of blood collection, and smoking status. RESULTS: Mean estimated glomerular filtration rate was 86 mL/min per 1.73 m(2) in cases and controls. At baseline, there were no statistically significant differences between cases and controls in plasma levels of FGF23, PTH, or phosphorus. After adjusting for matching factors, family history of myocardial infarction, body mass index, alcohol consumption, physical activity, history of diabetes mellitus and hypertension, ethnicity, region, plasma 25-hydroxyvitamin D, and other factors, the odds ratios for incident CHD for participants in the highest, compared with lowest, quartiles were 1.03 (95% CI 0.70-1.52, P for trend 0.84) for FGF23, 1.20 (95% CI 0.82-1.76, P trend 0.99) for PTH, and 0.72 (95% CI 0.51-1.02, P trend 0.13) for phosphorus. CONCLUSIONS: Plasma FGF23, PTH, and phosphorus are not associated with the development of incident CHD in men without chronic kidney disease.
BACKGROUND:Fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and phosphorus all have been proposed as plasma biomarkers for the development of coronary heart disease (CHD) in individuals with normal renal function. METHODS: In a nested case-control study of men in the Health Professionals Follow-up Study, free of diagnosed cardiovascular disease at blood draw, we prospectively examined associations between plasma FGF23, PTH, and phosphorus and risk of CHD. During 10 years of follow-up, 422 men developed nonfatal myocardial infarction or fatal CHD. Controls were selected in a 2:1 ratio and matched for age, date of blood collection, and smoking status. RESULTS: Mean estimated glomerular filtration rate was 86 mL/min per 1.73 m(2) in cases and controls. At baseline, there were no statistically significant differences between cases and controls in plasma levels of FGF23, PTH, or phosphorus. After adjusting for matching factors, family history of myocardial infarction, body mass index, alcohol consumption, physical activity, history of diabetes mellitus and hypertension, ethnicity, region, plasma 25-hydroxyvitamin D, and other factors, the odds ratios for incident CHD for participants in the highest, compared with lowest, quartiles were 1.03 (95% CI 0.70-1.52, P for trend 0.84) for FGF23, 1.20 (95% CI 0.82-1.76, P trend 0.99) for PTH, and 0.72 (95% CI 0.51-1.02, P trend 0.13) for phosphorus. CONCLUSIONS: Plasma FGF23, PTH, and phosphorus are not associated with the development of incident CHD in men without chronic kidney disease.
Authors: A Ascherio; E B Rimm; E L Giovannucci; G A Colditz; B Rosner; W C Willett; F Sacks; M J Stampfer Journal: Circulation Date: 1992-11 Impact factor: 29.690
Authors: E Giovannucci; G Colditz; M J Stampfer; E B Rimm; L Litin; L Sampson; W C Willett Journal: Am J Epidemiol Date: 1991-04-15 Impact factor: 4.897
Authors: S Chasan-Taber; E B Rimm; M J Stampfer; D Spiegelman; G A Colditz; E Giovannucci; A Ascherio; W C Willett Journal: Epidemiology Date: 1996-01 Impact factor: 4.822
Authors: Ravi Dhingra; Lisa M Sullivan; Caroline S Fox; Thomas J Wang; Ralph B D'Agostino; J Michael Gaziano; Ramachandran S Vasan Journal: Arch Intern Med Date: 2007-05-14
Authors: Casey M Rebholz; Morgan E Grams; Josef Coresh; Elizabeth Selvin; Lesley A Inker; Andrew S Levey; Paul L Kimmel; Ramachandran S Vasan; John H Eckfeldt; Harold I Feldman; Chi-Yuan Hsu; Pamela L Lutsey Journal: J Am Soc Nephrol Date: 2014-07-24 Impact factor: 10.121
Authors: Á Aceña; A M Pello; R Carda; Ó Lorenzo; M L Gonzalez-Casaus; L M Blanco-Colio; J L Martín-Ventura; J Palfy; M Orejas; R Rábago; E Gonzalez-Parra; I Mahíllo-Fernández; J Farré; J Egido; J Tuñón Journal: J Nutr Health Aging Date: 2016 Impact factor: 4.075
Authors: Bhupesh Panwar; Nancy S Jenny; Virginia J Howard; Virginia G Wadley; Paul Muntner; Brett M Kissela; Suzanne E Judd; Orlando M Gutiérrez Journal: Stroke Date: 2015-01-06 Impact factor: 7.914
Authors: Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón Journal: J Bone Miner Metab Date: 2015-08-23 Impact factor: 2.626
Authors: Clinton B Wright; Nirav H Shah; Armando J Mendez; Janet T DeRosa; Mitsuhiro Yoshita; Mitchell S V Elkind; Ralph L Sacco; Charles DeCarli; Tatjana Rundek; Shonni Silverberg; Chuanhui Dong; Myles Wolf Journal: Stroke Date: 2016-03-08 Impact factor: 7.914
Authors: Chad D Touchberry; Troy M Green; Vladimir Tchikrizov; Jaimee E Mannix; Tiffany F Mao; Brandon W Carney; Magdy Girgis; Robert J Vincent; Lori A Wetmore; Buddhadeb Dawn; Lynda F Bonewald; Jason R Stubbs; Michael J Wacker Journal: Am J Physiol Endocrinol Metab Date: 2013-02-26 Impact factor: 4.310